The pilots, developed in partnership with two life insurance companies, are designed to explore how the M-Panel predictive epigenetic technology can be best applied to insurance products and services. As part of scaling up its operational capabilities, Life Epigenetics has set up a global network of suppliers and test facilities that enable it to analyze tens of thousands of saliva samples per month. And, Life Epigenetics has established research partnerships with two major universities.
Life Epigenetics, the insurtech subsidiary of GWG Holdings, Inc. (Nasdaq:GWGH), announced that two major life insurance companies will begin pilot programs to test its epigenetic-based M-Panel technology. Life Epigenetics holds the exclusive license for lifespan-predictive technology developed at the University of California, Los Angeles (UCLA) for the life insurance industry. Since February the company has been collecting and analyzing data from life insurance policyholders. The pilot programs with the two life insurance companies are intended to demonstrate new ways epigenetic data can be used to improve underwriting efficiency and precision.